Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772005 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
- 287
- Enrollment target
- 20
- Study locations
NCT00772005: Completed Phase 2 study of Schizophrenia, sponsored by Cephalon.
NCT00772005 is a Phase 2 study of Schizophrenia that has completed, run by Cephalon. The registered enrollment target is 287 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00772005, a Phase 2 study of Schizophrenia, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 287 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the negative symptoms of schizophrenia
Primary Outcome
PANSS rates severity of psychopathology in schizophrenics. 7 items measure NEGATIVE symptoms: blunted affect, social withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. Each item is scored on a 7-point severity scale: 1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate severe, 6=severe, 7=extreme. Negative Scale score ranges from 7-49 (higher more severe). Data represents change in Neg
Conditions Studied
Interventions
- DRUG placebo
- DRUG armodafinil
Study Locations (20)
California
- Omega Clinical Trials - Anaheim
- Synergy Clinical Research Center - Escondido
- Collaborative NeuroScience - Garden Grove
- Excell Research - Oceanside
- CNRI Los Angeles LLC - Pico Rivera
- CNRI-San Diego LLC - San Diego
- Neuropsychiatric Research Center of Orange County - Santa Ana
- Collaborative NeuroScience Network - Torrance
Florida
- Scientific Clinical Research, Inc. - Aventura
- Mental Health Advocates. Inc - Boca Raton
- Fidelity Clinical Research - Lauderhill
- Stedman Clinical Trials, LLC - Tampa
Georgia
- Atlanta Center for Medical Research - Atlanta
- Comprehensive Neuroscience Inc - Atlanta
- Carman Research - Smyrna
Connecticut
- The Hospital of Central Connecticut - New Britain
- Yale University School of Medicine - New Haven
Arkansas
- K and S Professional Research Services, LLC - Little Rock
Illinois
- Uptown Research Institute. LLC - Chicago
Kansas
- Via Christi Research - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00772005 record still lists
NCT00772005 is an interventional study that assigns participants to a tested intervention. The registered 287 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (32% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00772005 names 20 study sites across 7 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00772005 about?
NCT00772005 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia". The primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the negative symptoms of schizophrenia
What is the current status of trial NCT00772005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 287 participants. The study started on 2008-09. Estimated completion is 2010-05.
What conditions does trial NCT00772005 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00772005?
The interventions under investigation include: placebo (DRUG), armodafinil (DRUG).
Who is sponsoring clinical trial NCT00772005?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00772005 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00772005's enrollment target sits among peer trials
287 65th of 315 higher than 251 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03094429 · 287 participants · Phase 2
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- NCT06385080 · 287 participants · Phase 1
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- NCT06919224 · 287 participants · NA
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia